<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972839</url>
  </required_header>
  <id_info>
    <org_study_id>29BRC19.0034</org_study_id>
    <nct_id>NCT03972839</nct_id>
  </id_info>
  <brief_title>Comparison of Two D-Dimers Dosing Techniques</brief_title>
  <acronym>COMPADDI</acronym>
  <official_title>Comparison of Two D-Dimers Dosing Techniques : LIATEST DDI PLUS (STAGO) Versus VIDAS D-DIMERS (BIOMERIEUX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the possibility of substitution of the automated STAGO D-Dimers method with the
      semi-automated VIDAS method, which is more expensive, longer to implement and requires the
      use of a dedicated automaton.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare D-Dimer assay techniques in the exclusion of VTE (Thromboembolic Venous Disease):•
      BIOMERIEUX: D-Dimers VIDAS (considered as reference technique)• STAGO: D-Di PlusOn a
      population of patients recruited in Brest for a period of 1 year: patients for whom a dosage
      of VIDAS D-dimers is prescribed (approximately 3700 patients)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomerieux D-Dimer level</measure>
    <time_frame>at the inclusion</time_frame>
    <description>quantification of Biomerieux D-Dimer level (VIDAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stago D-Dimer level</measure>
    <time_frame>at the inclusion</time_frame>
    <description>quantification of Biomerieux D-Dimer level (STAGO)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3700</enrollment>
  <condition>Blood Coagulation Disorder</condition>
  <arm_group>
    <arm_group_label>D-Dimers patients</arm_group_label>
    <description>population recruited in Brest for a period of 1 year: patients for whom a dose of VIDAS D-dimers is prescribed (approximately 3700 patients)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient population recruited in Brest for a period of 1 year: patients for whom a dose of
        VIDAS D-dimers is prescribed (approximately 3700 patients)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients for whom a dosage of D-Dimers VIDAS is prescribed in the context of a
             suspicion of VTE at Brest CHRU.

          -  No opposition formulated.

        Exclusion Criteria:

          -  Curative dose anticoagulant treatment whatever the indication,

          -  Pregnancy in progress,

          -  Follow-up at 3 months not possible,

          -  Patient refusing to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fanny MINGANT</last_name>
    <phone>33-298347036</phone>
    <email>fanny.mingant@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hubert GALINAT</last_name>
    <email>hubert.galinat@chu-brest.fr</email>
  </overall_contact_backup>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Coagulation</keyword>
  <keyword>DDimers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

